Related Experiment Video
Updated: Aug 25, 2026
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
Heterocyclic Scaffolds in PARP-1 Inhibition: An Emerging Strategy for Targeted Anticancer Therapy
Hardha Balachandran1, Gowramma Byran1, Veera Venkata Satyanarayana Reddy Karri2
1Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education and Research.
Introduction:
Poly (ADP-ribose) polymerase-1 (PARP-1) is a key regulator of DNA repair, genomic stability, and programmed cell death. PARP-1 inhibition induces synthetic lethality in homologous recombination-deficient tumors, particularly those with BRCA mutations. Firstgeneration PARP inhibitors, including Olaparib, Niraparib, Talazoparib, and Rucaparib, have significantly advanced targeted cancer therapy but are limited by toxicity, resistance, and off-target effects. This review aims to highlight the potential of heterocyclic scaffolds for developing selective and improved PARP-1 inhibitors, with emphasis on structure-activity relationships and optimization strategies.
Methods:
Published literature, crystallographic studies, and preclinical evaluations were analysed to assess heterocyclic frameworks such as quinazolines, benzimidazoles, oxadiazoles, thiadiazoles, triazoles, and indoles. Design strategies including scaffold hopping, bioisosteric replacement, and hybrid design were evaluated for their impact on potency, selectivity, and pharmacological performance.
Results:
Heterocyclic scaffolds demonstrated strong binding to the PARP-1 catalytic domain through hydrogen bonding and π-π stacking with key residues (e.g., Gly863 and Tyr907). SAR studies showed that halogenation, methoxy substitution, Schiff bases, and azole linkers enhanced potency, solubility, and pharmacokinetics. Next-generation scaffolds, such as triazolo-pyrazines and benzimidazoles, exhibited improved PARP-1 selectivity over PARP-2, reducing haematological toxicity and improving antiproliferative activity in BRCA-mutated models.
Discussion:
Rational heterocycle-based design improves selectivity, metabolic stability, and tumor targeting, addressing key limitations of existing PARP inhibitors.
Conclusion:
Heterocyclic scaffolds offer a promising route toward next-generation PARP-1 inhibitors with enhanced efficacy, reduced resistance, and optimized safety, supporting personalized anticancer therapy.
Insights
Heterocyclic scaffolds offer a promising path to develop next-generation Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors. These novel compounds show enhanced efficacy and safety for targeted cancer therapy, particularly in BRCA-mutated tumors.
Area of Science:
- Medicinal Chemistry
- Oncology
- Drug Discovery
Background:
- Poly (ADP-ribose) polymerase-1 (PARP-1) is crucial for DNA repair and genomic stability.
- PARP-1 inhibitors are vital for treating homologous recombination-deficient tumors, especially those with BRCA mutations.
- Existing PARP inhibitors face challenges including toxicity, resistance, and off-target effects.
Purpose of the Study:
- To review the potential of heterocyclic scaffolds in developing selective and improved PARP-1 inhibitors.
- To emphasize structure-activity relationships and optimization strategies for novel PARP-1 inhibitors.
Main Methods:
- Analysis of published literature, crystallographic studies, and preclinical data on heterocyclic frameworks.
- Evaluation of design strategies like scaffold hopping and bioisosteric replacement.
- Assessment of impact on inhibitor potency, selectivity, and pharmacological performance.
Main Results:
- Heterocyclic scaffolds bind effectively to the PARP-1 catalytic domain via hydrogen bonding and π-π stacking.
- Specific modifications (halogenation, methoxy substitution, azole linkers) enhance potency, solubility, and pharmacokinetics.
- Next-generation scaffolds demonstrate improved PARP-1 selectivity over PARP-2, reducing toxicity and enhancing antiproliferative activity.
Conclusions:
- Rational heterocycle design enhances selectivity, metabolic stability, and tumor targeting of PARP-1 inhibitors.
- Heterocyclic scaffolds represent a promising strategy for next-generation PARP-1 inhibitors with improved efficacy, reduced resistance, and optimized safety.
- This approach supports the advancement of personalized anticancer therapy.
More Related Videos
07:53Visualization and Quantitative Analysis of Genotoxin-Induced PARP1/PARP2 Activation in Cells Using a Fluorescent Fusion Protein-Based Reporter
Published on: April 17, 2026
15:53Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:34Inhibition of Cdk Activity
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...